China Biologic Products (CBPO) Getting Somewhat Positive Press Coverage, Analysis Finds
Media stories about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. China Biologic Products earned a news impact score of 0.11 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.2041123514363 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Intravenous Immunoglobulin Market by IGA, IGD, IGE, IGG, IGM Type, Analysis and Forecasts to 2023 (abnewswire.com)
- Analyst’s Buy rated Stock: China Biologic Products Holdings, Inc. (CBPO) – Street Observer (press release) (streetobserver.com)
- China Biologic Products (CBPO) Granted from Approval Chinese FDA for Commercial Manufacturing of Human … – StreetInsider.com (streetinsider.com)
- China Biologic Products (CBPO) Granted from Approval Chinese FDA for Commercial Manufacturing of Human Fibrinogen (streetinsider.com)
- BRIEF-China Biologic receives approval for commercial manufacturing of human fibrinogen (reuters.com)
China Biologic Products (CBPO) opened at 97.45 on Wednesday. The stock has a market capitalization of $2.65 billion, a P/E ratio of 25.36 and a beta of 1.75. China Biologic Products has a 1-year low of $88.25 and a 1-year high of $125.99. The stock has a 50 day moving average of $93.59 and a 200 day moving average of $103.42.
China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. The firm had revenue of $89.28 million for the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The firm’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 EPS. On average, analysts expect that China Biologic Products will post $4.95 earnings per share for the current year.
Several equities analysts have recently weighed in on CBPO shares. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. China Biologic Products has a consensus rating of “Hold” and a consensus target price of $137.50.
TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/11/china-biologic-products-cbpo-getting-somewhat-positive-press-coverage-analysis-finds.html.
About China Biologic Products
Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.